Palatin Technologies, Inc. · AMEX:PTN

Palatin Technologies — Investor Presentation (January 2015)

35 slides from Palatin Technologies's investor presentation, January 2015

  1. Slide 1: Palatin Technologies

    Palatin Technologies January 2015 Carl Spana, Ph.D. President & CEO Stephen T. Wills, CPA/MST CFO / COO

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements The statements in this presentation that relate to future plans, events or performance are forward-looking statements, which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended. Such forward-looking statements involve si

  3. Slide 3: Company Profile

    Company Profile Palatin Technologies, Inc. (NYSE MKT: PTN) is a biopharmaceutical company developing targeted, receptor- specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. 3

  4. Slide 4: Palatin Technologies Value Proposition

    Palatin Technologies Value Proposition  Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential  Lead product: Bremelanotide (BMT) for the treatm

  5. Slide 5: Pipeline Overview

    Pipeline Overview Preclinical Phase 1 Phase 2 Phase 3 Melanocortin Receptor Programs Bremelanotide for Female Sexual Dysfunction MC4r Agonist AstraZeneca Collaboration Obesity, Metabolic Syndrome & Diabetes MC4r Agonist Female Sexual Dysfunction & Erectile Dysfunction Next Generation Peptide PL-8177

  6. Slide 6: Female Sexual Dysfunction Program

    Female Sexual Dysfunction Program

  7. Slide 7: Female Sexual Dysfunction Overview

    Female Sexual Dysfunction Overview  Female Sexual Dysfunction (FSD) is defined as persistent or recurring problems during one or more of the stages of sexual response with associated distress  FSD has a significant impact on patient self-image, relationships and general well-being  >60 million pr

  8. Slide 8: Approaches to Treating FSD

    Approaches to Treating FSD  Low dose transdermal testosterone in surgically menopausal Hypoactive Sexual Desire Disorder (HSDD) patients. ◦ Intrinsa testosterone patch successful Phase 3 program – Failure to approve based on long term use safety risks of cancer and cardiovascular adverse events ◦ L

  9. Slide 9: Bremelanotide Profile

    Bremelanotide Profile  Novel mechanism of action activating endogenous melanocortin hormone pathways involved in sexual arousal response  Evaluated in 31 clinical studies (n = 2300) showing efficacy in both FSD and erectile dysfunction  Phase 2B trial showed a statistically significant and clinic

  10. Slide 10: Phase 2B FSD Clinical Trial

    Phase 2B FSD Clinical Trial  Dose ranging 16 week at-home placebo-controlled study ◦ Subcutaneous dosing: placebo and 0.75 mg, 1.25 mg and 1.75 mg bremelanotide ◦ Enrollment: 395 patients  Validated patient reported outcome (PRO) endpoints ◦ Increase in Satisfying Sexual Events (SSEs) – As measure

  11. Slide 11: Phase 2B FSD Clinical Data

    Phase 2B FSD Clinical Data  Analysis of the primary and key secondary endpoints of 327 pre-menopausal patients shows clinically meaningful and statistically significant effects for bremelanotide vs. placebo. Pre-specified analysis was of pooled 1.25 mg & 1.75 mg doses vs. placebo.  Primary endpoin

  12. Slide 12: Phase 2B FSD Clinical Data

    Phase 2B FSD Clinical Data 0.9 SSE 5.0 FSFI Total Score 0.0 Placebo 0.75 mg 1.25 mg 1.75 mg 0.8 * 4.5 ** -2.0 4.0 0.7 Mean Change From Baseline Mean Change From Baseline Mean Change From Baseline 3.5 -4.0 0.6 3.0 0.5 * -6.0 2.5 0.4 2.0 -8.0 0.3 1.5 * -10.0 0.2 1.0 0.1 0.5 -12.0 FSDS-DAO Total Score

  13. Slide 13: Phase 2B FSD Clinical Data

    Phase 2B FSD Clinical Data  395 premenopausal FSD patients were randomized to receive drug or placebo  26 patients met the predefined blood pressure withdrawal criteria and were evenly distributed among placebo and active arms of the study  Drug treated subjects had ~2 mm Hg change in blood press

  14. Slide 14: Phase 3 NA Pivotal Program

    Phase 3 NA Pivotal Program  Key Points ◦ Patient population – HSDD & HSDD with decreased arousal ◦ 24 week treatment evaluation period ◦ Co-primary endpoints – SSE and FSFI Desire subdomain (28 day recall) ◦ Key secondary endpoint – FSDS-R (revised) question #13 ◦ 1.75 mg versus placebo ◦ Cardio-Re

  15. Slide 15: Phase 2B Analyzed for Phase 3 Patient Population & Endpoints

    Phase 2B Analyzed for Phase 3 Patient Population & Endpoints SSE FSFI-Desire FSDS-Q13 0.8 1.2 0 P=0.03 0.7 1 P=0.001 -0.25 0.6 0.8 0.5 -0.5 0.4 0.6 -0.75 0.3 0.4 0.2 -1 0.2 P=0.008 0.1 0 0 -1.25 Placebo 1.25mg 1.75mg Placebo 1.25mg 1.75mg Placebo 1.25mg 1.75mg Phase 2B data from patients diagnosed w

  16. Slide 16: Corporate Partnering

    Corporate Partnering  European rights licensed to Gedeon Richter (August 2014) ◦ European pharmaceutical company with a focus on female healthcare - $1.6B in 2013 sales - $500M in female healthcare ◦ EMA/ CHMP guidance on the EU Phase 3 program received ◦ Jointly working on EU Phase 3 clinical deve

  17. Slide 17: Key Points FDA Public Meeting on FSD

    Key Points FDA Public Meeting on FSD  On October 27 & 28, 2014 the FDA held a Patient-Focused Drug Development Public Meeting and Scientific Workshop on Female Sexual Dysfunction ◦ FSD is an underserved, unmet medical need that distresses patients and is in need of multiple treatment options ◦ FDA

  18. Slide 18: Bremelanotide NA & EU Program Timelines

    Bremelanotide NA & EU Program Timelines  NA (primarily U.S.) ◦ Phase 3 pivotal trials enrolling patients 4Q2014 ◦ Complete Phase 3 enrollment 2H2015 ◦ Phase 3 trials topline results Mid-2016 ◦ FDA NDA submission 4Q2016 ◦ FDA action 4Q2017  EU ◦ EMA/CHMP guidance - completed 1H2014 ◦ Commence Pha

  19. Slide 19: Natriuretic Peptide Receptor Program

    Natriuretic Peptide Receptor Program

  20. Slide 20: Natriuretic Peptide System

    Natriuretic Peptide System Neuropeptide hormone system Prohormone plays an important role in the regulation of cardiovascular homeostasis CNP BNP ANP Corin processing Neutral endopeptidase (neprilysin) And the NP-C receptor downregulate GTP PKG the NP system through removal of active ANP, BNP and CN

  21. Slide 21: Paradigm Shift in HF: Upregulation of NP System

    Paradigm Shift in HF: Upregulation of NP System  LCZ696 (Novartis compound) – combined ARB & neprilysin inhibitor ◦ Inhibits angiotensin function and upregulates endogenous natriuretic peptides  Phase 3 trial in heart failure (HF) patients with reduced ejection fraction compared LCZ696 to ACEi (en

  22. Slide 22: Overview Palatin Natriuretic Peptide Program

    Overview Palatin Natriuretic Peptide Program  Design and develop commercial candidates selective for NPR-A, NPR-B, NPR-C & NPR-A/B  PL-3994 lead product candidate ◦ Selective NPR-A agonist ◦ Increased metabolic stability ◦ Once daily subcutaneous (SC) patient administration ◦ Phase 2 ready drug de

  23. Slide 23: Daily PL-3994 Significantly Reduces Cardiac Remodeling

    Daily PL-3994 Significantly Reduces Cardiac Remodeling Heart Weight /Body Weight Attenuation of RAAS Activation following 6 weeks of treatment 0.6 80000 * * * Plasma aldosterone 60000 * p < 0.05 0.4 HW/BW 40000 2K1C (saline) (pg/ml) 2K1C (PL3994) 0.2 20000 * p < 0.05 2000 * 0.0 1000 0 ) e) 4) e) 4 i

  24. Slide 24: Opportunities for Treating Heart Failure

    Opportunities for Treating Heart Failure  Heart Failure with Preserved  Phase 2A multiple dose study in HF Ejection Fraction (HF-PEF) patients ◦ High unmet need; no approved ◦ HF-PEF, HF-REF & corin deficient patients treatment options ◦ Evaluate safety, symptom relief and cardiac imaging, LVEF 

  25. Slide 25: Melanocortin Receptor-1 Agonists Inflammation and Dermatologic Indications

    Melanocortin Receptor-1 Agonists Inflammation and Dermatologic Indications

  26. Slide 26: MC1r Agonist Anti-Inflammatory Program

    MC1r Agonist Anti-Inflammatory Program  Goal: design and develop selective MC1r agonists for treating a variety of inflammatory and autoimmune indications ◦ Inflammatory indications: inflammatory bowel disease, nephritis (inflammation of the kidneys) and rheumatoid arthritis ◦ Ocular indications: u

  27. Slide 27: TNF-α Inhibition via MC1r Agonists

    TNF-α Inhibition via MC1r Agonists Results 3000 Dose – mg/kg SC pmole/mL TNFa 2000 1000 0 1 1 le 10 10 5 @ @ @ ic @ @ eh 76 77 a 76 77 ex V 1 1 1 1 L8 L8 D L8 L8 P P P P Preclinical mouse model TNF-α stimulated by LPS administration with dexamethasone as positive control 27

  28. Slide 28: PL-8177 Experimental Autoimmune Uveitis

    PL-8177 Experimental Autoimmune Uveitis Untreated EAU mice PL-8177 Low Dose Treated EAU mice PL-8177 High Dose Treated EAU mice 4 α-MSH Treated EAU mice EAU Clinical Score 3 2 * 1 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Day Days of injections * P = 0.0001 by Anova ◦ MC1r agonism ha

  29. Slide 29: Melanocortin Receptor-4 Agonist Obesity & Diabetes

    Melanocortin Receptor-4 Agonist Obesity & Diabetes

  30. Slide 30: Melanocortins and Obesity Overview

    Melanocortins and Obesity Overview Hypothalamus arcuate nucleus Stimulates MC4r – decrease in food intake & weight loss POMC Brainstem & Cortex Peripheral Signals MC4r signals Leptin Grelin GLP-1 Down stream effects on Insulin food intake, weight CCK and energy expenditure AGRP Inhibits MC4r – incre

  31. Slide 31: MC4r Obesity & Diabetes Program

    MC4r Obesity & Diabetes Program  Goal: design and develop selective for MC4r agonists for treating obesity, diabetes and related metabolic syndrome ◦ High selectivity for MC4r with limited off-target effect ◦ None of the toxicities associated with small molecules  Lead compound PL-8905 ◦ High sele

  32. Slide 32: AstraZeneca Obesity Collaboration

    AstraZeneca Obesity Collaboration  Exclusive global licensing and research collaboration ◦ $10M upfront and $10M milestones received ◦ $145M in additional potential milestones ◦ Royalties on sales of approved products  Clinical proof-of-concept studies for MC4r mechanism have been completed ◦ Prim

  33. Slide 33: Palatin Potential Near-Term Development Milestones

    Palatin Potential Near-Term Development Milestones  Bremelanotide for Female Sexual Dysfunction ◦ Commence Phase 3 pivotal trials in NA 4Q2014  ◦ Complete Phase 3 enrollment in NA 2H2015 ◦ Commence Phase 3 pivotal trial in EU 2H2015 ◦ NA Phase 3 pivotal trial results Mid-2016 ◦ Corporate collabora

  34. Slide 34: Financial Snapshot

    Financial Snapshot Financial Highlights as of September 30, 2014 Cash & Equivalents $17.8 million1 Total Debt $0.01 Summary of Capitalization as of January 2015 Common Equivalent2 Common Stock 41.5 million shares Preferred 0.1 million shares Warrants 116.7 million shares3 Options 4.2 million shares

  35. Slide 35: Thank You

    <> Thank You

Palatin Technologies — Investor Presentation (January 2015) on 6ix